At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
Lamotrigine +1 moredrug
Likely dose
Lamotrigine 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression
Institute of Social Security of the Civil Servants of Minas Gerais·interventional·Posted Apr 3, 2008·Updated Apr 9, 2008
In Brief
A Phase 3 clinical trial evaluating Lamotrigine and Amide for Depression. Completed, enrolled 34 participants.
Detailed Summary
This study reports a clinical trial evaluating lamotrigine safety and efficacy as an antidepressant augmentation agent in treatment resistant depression, therefore adding more empirical evidence to the limited number of studies on the use of lamotrigine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
Primary CompletionJan 2006
First PostedApr 2008
TodayJul 2026
First PostedApr 3, 2008
Enrollment StartJan 1, 2004
Primary CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.2 years ago
Interventions
Lamotriginedrug
Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
Amidedietary
Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.